26Jul/13

AbbVie Inc. (ABBV) CEO Discusses Q2 2013 Results – Earnings Call Transcript – Seeking Alpha

AbbVie Inc. (ABBV) CEO Discusses Q2 2013 Results – Earnings Call Transcript
Seeking Alpha
Daclizumab, currently in Phase III development in partnership with Biogen for multiple sclerosis – our second pivotal study will read out next year and we’re planning global registration submissions in 2014 as well. Elagolix is being evaluated in Phase

and more »